Common questions about Xiaflex (FAQ)
Q: Does Xiaflex permanently cure the condition, or is it a temporary fix?
Official information from clinical studies indicates that the long-term duration and durability of the treatment effect have not been fully characterized. Research monitored study participants for the subsequent recurrence of the cord or plaque over time. Patients are instructed to follow their provider's guidance regarding long-term care and monitoring.
Q: How long after the injection should I expect to see a change?
According to the official product information, the treatment is part of a structured process where the enzyme's effect is followed by a mechanical procedure performed by a healthcare provider. For Dupuytren's contracture, the product information states the provider may perform the cord disruption procedure approximately 24 to 72 hours after the injection. For Peyronie's disease, the modeling procedure is done a few days after the second injection in a cycle.
Q: If I have a history of a different medical condition, can I still get Xiaflex?
The label requires patients to inform their healthcare provider about all medical conditions and all medicines being taken. Official regulatory information advises caution, particularly for patients with bleeding problems or abnormal coagulation. The full prescribing information lists specific conditions that may prevent the use of the medicine, known as absolute contraindications.
Q: What does it mean if the treatment is 'non-surgical'?
Xiaflex is a non-surgical treatment option because it is administered as a local injection directly into the abnormal fibrous tissue. The medicine works by chemically degrading the tissue, which distinguishes it from surgical procedures that involve cutting or incising the tissue.
Q: Does Xiaflex work for all stages of Dupuytren's contracture?
Official documentation indicates that Xiaflex is specifically approved for adult patients with Dupuytren's contracture who have a palpable cord. The therapy is not intended for all stages or manifestations of the condition. Patients must meet specific eligibility criteria defined in the product labeling.
Q: Do I need to do physical therapy after a Xiaflex injection?
The treatment protocol includes specific post-injection procedures, such as finger extension (for Dupuytren's) or manual stretching and modeling (for Peyronie’s). Patients are required to adhere to the specific exercise and movement regimen provided in the treatment protocol.
Q: Why is Xiaflex only approved for certain types of contractures?
The drug's approval is limited to specific anatomical and condition criteria based on the populations studied in clinical trials. For example, it is contraindicated (must not be used) for Peyronie’s plaques that involve the penile urethra due to the potential risk of injury to that structure.
Q: Are there long-term side effects noted in the research studies?
Official research data on Xiaflex has not fully characterized the long-term safety profile, as the main clinical trials focused on efficacy and safety measurements within the first year or two after treatment. Information on adverse reactions that may occur many years after treatment is limited.
Q: What kind of specialist usually administers Xiaflex?
According to the official product information, Xiaflex must be administered by a physician who has been appropriately trained. Official documents state the physician must be experienced in performing the correct injection procedure and in the diagnosis and management of the condition being treated, such as a hand specialist or a urologist.
Q: Is the pain from the injection severe?
Pain at the injection site is listed as a common adverse reaction in regulatory documents. Official information advises that if a patient experiences dizziness or feels faint, which can occur after injection due to pain, they should lie down until symptoms resolve. Patients are instructed to follow their provider's guidance on pain management.
Q: Is Xiaflex used for treating anything other than Dupuytren's contracture and Peyronie's disease?
According to official regulatory indications, Xiaflex is only approved for the treatment of adult patients with Dupuytren's contracture with a palpable cord and adult men with Peyronie's disease with a palpable plaque and curvature deformity.
Q: How is Xiaflex different from having surgery for Dupuytren's?
The official documentation defines Xiaflex as a procedure involving a local injection, which is classified as a non-surgical option. Research on Xiaflex focuses on its efficacy compared to an inactive placebo injection, and official evidence does not currently provide comparisons against all available surgical procedures.
Q: Can I drive immediately after getting a Xiaflex injection?
The official medication guide notes that fainting (syncope) or near-fainting can occur, sometimes related to pain, after the injection. Regulatory information advises that if a patient feels dizzy or faint, they should lie down until the symptoms pass. Patients must follow their provider's specific instructions regarding resuming activities and driving.
Q: Can I take over-the-counter pain relievers after the treatment?
Government-sourced health content often suggests that over-the-counter (OTC) pain medicines can be used for mild to moderate pain in the treated area. Regulatory sources advise patients to check with their healthcare provider to confirm the safety of using any specific medication.
Q: Why does the treatment process take multiple injections and visits?
Official administration guidelines define the treatment as a structured protocol. This multi-step process is required to allow the medicine's highly localized enzymatic action to soften the cord or plaque over time, facilitating the necessary mechanical procedures performed by the healthcare provider to achieve the final outcome.
Q: What should I do if the treated area feels numb or cold?
The official medication guide instructs patients to contact their healthcare provider right away if they notice signs of potential injury. This includes symptoms such as numbness or tingling in a treated finger (Dupuytren's) or other severe or unusual symptoms in the treated area.
Q: Why is the drug administered only by a healthcare provider?
The drug must be administered by a qualified healthcare provider due to the specialized injection technique required to correctly target the fibrous tissue. This is also mandated because of the risk of serious adverse reactions, such as tendon rupture or corporal rupture, which require physician oversight and sometimes a restricted access program (REMS).
Q: Can Xiaflex be used on other joints besides the hand or penis?
Official regulatory indications restrict the use of Xiaflex to the treatment of Dupuytren's contracture with a palpable cord and Peyronie's disease with a palpable plaque. The medicine is not approved for use in other joints or tissues.
Q: Why are people sometimes unable to receive the second injection in a series?
Subsequent injections in a treatment series are always dependent on the clinical assessment of the treatment response. If the treatment is deemed successful by the healthcare provider, having met the defined endpoint (such as achieving a specific angle of extension or curvature), further injections may not be clinically necessary.
Q: What is the Black Box Warning associated with Xiaflex?
Xiaflex carries a regulatory requirement for a Boxed Warning (often called a 'Black Box Warning') concerning the risk of Penile Fracture (Corporal Rupture) or other serious penile injury. This warning applies specifically when the drug is used to treat Peyronie’s disease.
Q: How soon can I return to strenuous activity after treatment?
Official post-treatment instructions require patients to limit motion and avoid activities that may cause straining of the injected area. For Peyronie's disease, sexual activity must be avoided for at least four weeks after the second injection in a treatment cycle.
Q: Why is it important to keep the limb elevated after the procedure?
Patients are officially instructed to keep the injected hand elevated (in the case of Dupuytren's) until bedtime on the day of injection. This is a common post-procedure instruction intended to help reduce and manage localized swelling or edema, which is a very common adverse reaction.
Q: Is swelling a sign that the medication is working?
Swelling (peripheral edema or penile swelling) is listed in official documentation as a very common adverse reaction to the injection. While the medicine does cause localized tissue changes, swelling is classified as an expected side effect, not explicitly as a sign of efficacy.
Q: What should I do if I get a fever after the injection?
Official health guidance instructs patients to contact their healthcare provider right away if they notice signs of a potential serious reaction or infection. These signs include fever, chills, or increased redness or swelling in the treated area.
Q: Are there any known interactions between Xiaflex and common herbal supplements?
The official label instructs patients to tell their healthcare provider about all the medicines they take, including prescription and non-prescription medicines, vitamins, and herbal supplements. This is a precaution, as using Xiaflex with certain other medicines could cause serious side effects.
Q: Can I receive Xiaflex if I have previously had surgery for the condition?
The main clinical trials generally excluded patients who had previously undergone surgery on the affected area. Therefore, the official information does not fully characterize the impact of treating a cord or plaque with Xiaflex if it is in an area that has previously been operated on.
Q: Why is this drug used for two very different conditions?
The drug’s mechanism of action explains its use, as it is composed of enzymes that specifically target and degrade collagen. This protein is the main structural component of the abnormal, restrictive fibrous tissue (the cord or plaque) that characterizes both Dupuytren's contracture and Peyronie's disease.
